Tumour regression in non-small-cell lung cancer following neoadjuvant therapy, A significant prognostic factor

1998 ◽  
Vol 124 (5) ◽  
pp. 283-284 ◽  
Author(s):  
K. Junker
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Tumour Regression ◽  
Significant Prognostic Factor ◽  
Small Cell Lung

Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment

1997 ◽  
Vol 123 (9) ◽  
pp. 469-477 ◽  
Author(s):  
K. Junker ◽  
M. Thomas ◽  
K. Schulmann ◽  
F. Klinke ◽  
U. Bosse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Tumour Regression ◽  
Small Cell Lung ◽  
Histological Assessment

Maspin gene expression is a significant prognostic factor in resected non-small cell lung cancer (NSCLC)

Lung Cancer ◽  
2006 ◽  
Vol 51 (3) ◽  
pp. 323-328 ◽  
Author(s):  
Hiromichi Katakura ◽  
Kazumasa Takenaka ◽  
Masatsugu Nakagawa ◽  
Makoto Sonobe ◽  
Masashi Adachi ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Significant Prognostic Factor ◽  
Small Cell Lung

scholarly journals Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer

2021 ◽  
Author(s):  
Ari Nishimura ◽  
Akira Ono ◽  
Kazushige Wakuda ◽  
Takanori Kawabata ◽  
Michitoshi Yabe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Significant Prognostic Factor ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Median Percentage

SummaryBackground. Prognostic data on Japanese patients receiving durvalumab after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) are insufficient. Whether pneumonitis has prognostic implications in patients with LA-NSCLC who have received durvalumab also remains unclear. Methods. We retrospectively assessed the data of 82 consecutive patients who had received durvalumab after CRT at our institution between May 2018 and August 2020. A multi-state model was used to establish the associations between co-variables and progression-free survival (PFS). Results. The median observation period for all the censored cases was 14.5 months (5.7–28.9 months), the median PFS was 22.7 months, and the 12-month PFS rate was 62.3% (95% CI: 50.2%-72.3%). The median percentage of the lung volume receiving a radiation dose in excess of 20 Gray (V20) was 22% (4%-35%). Thirteen patients (16%) had Grade 1 pneumonitis before receiving durvalumab, and 62 patients developed pneumonitis after durvalumab (Grades 1, 2, and 3 in 25 [30%], 32 [39%], and 4 [5%], respectively). Twenty-four patients (29%) completed the 1-year durvalumab treatment period, 16 patients (20%) were continuing to receive treatment, and 42 (51%) had discontinued treatment. In a multi-state analysis, patients with pneumonitis before durvalumab therapy had a poorer PFS than those without pneumonitis (HR: 4.29, p = 0.002). The development of Grade 2 or higher pneumonitis after durvalumab was not a significant prognostic factor for PFS (HR: 0.71, p = 0.852). Conclusion. Grade 2 or higher pneumonitis after durvalumab was not a prognostic factor of PFS in LA-NSCLC patients received durvalumab.

Prognostic Impact of Pneumonitis After Durvalumab Therapy in Patients With Locally Advanced Non-small Cell Lung Cancer

2021 ◽  
Author(s):  
Ari Nishimura ◽  
Akira Ono ◽  
Kazushige Wakuda ◽  
Takanori Kawabata ◽  
Michitoshi Yabe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Significant Prognostic Factor ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Median Percentage

Abstract Background: Prognostic data on Japanese patients receiving durvalumab after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) are insufficient. Whether pneumonitis has prognostic implications in patients with LA-NSCLC who have received durvalumab also remains unclear.Methods: We retrospectively assessed the data of 82 patients who had received durvalumab after CRT at our institution between May 2018 and August 2020. A multi-state model was used to establish the associations between co-variables and progression-free survival (PFS).Results: The median observation period for all the censored cases was 14.5 months (5.7-28.9 months), the median PFS was 22.7 months, and the 12-month PFS rate was 62.3% (95% CI: 50.2%-72.3%). The median percentage of the lung volume receiving a radiation dose in excess of 20 Gray (V20) was 22% (4%-35%). Thirteen patients (16%) had Grade 1 pneumonitis before receiving durvalumab, and 62 patients developed pneumonitis after durvalumab (Grades 1, 2, and 3 in 25 [30%], 32 [39%], and 4 [5%], respectively). Twenty-four patients (29%) completed the 1-year durvalumab treatment period, 16 patients (20%) were continuing to receive treatment, and 42 (51%) had discontinued treatment. In a multi-state analysis, patients with pneumonitis before durvalumab therapy had a poorer PFS than those without pneumonitis (HR: 4.29, p = 0.002). The development of Grade 2 or higher pneumonitis after durvalumab was not a significant prognostic factor for PFS (HR: 0.71, p = 0.852).Conclusion: Grade 2 or higher pneumonitis after durvalumab was not a prognostic factor of PFS in LA-NSCLC patients received durvalumab.

Sign in / Sign up

Export Citation Format

Share Document